Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 The basic characteristics of participants

From: Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis

Variables

Study population

n = 45 (%)

Age

37.5 ± 6.51

Female

45 (100%)

Disease-modifying therapies

36(80.0%)

Interferon beta 1-a

Dimethyl fumarate

Fingolimod

Rituximab

Glatiramer acetate

12(33.35%)

5(13.9%)

6(16.7%)

12(33.35%)

1(2.7%)

Vaccine type

Sinopharm

Other

40(88.9%)

5(11.1%)

History of previous COVID-19 infection

19(42.2%)

Probable COVID-19 exposure

Regular contact (Daily)

No contact

Seldom contact

17(37.8%)

22(48.9%)

6(13.3%)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us